Skip to main content
. 2023 Jul 17;7(8):e0209. doi: 10.1097/HC9.0000000000000209

FIGURE 1.

FIGURE 1

Lenvatinib recruits GZMK + CD8 cells into HCC. (A) Modulated pathways in lenvatinib-treated HCC compared with matched control HCCs by bulk transcriptome profiling. (B) Accumulated immune cells in lenvatinib-treated and control HCC. p-values were corrected by Bonferroni correction. (C) Gene signature–based immune cell characterization. (D) Accumulated GZMK+CD8 T cells in the intratumor stroma and HCC cell area. Arrowheads indicate GZMK+CD8 T cells. Scale bar, 250 μm. (E) Number of GZMK+CD8 T cells in the intratumor stroma and HCC cell area. (F) Representative image of region selection in the DSP. Scale bar, 3 mm. (G) Expression pattern of immune-related genes in GZMK+CD8+T-cell-rich, GZMK-CD8+T cell–rich, and GZMK-CD8- regions. Abbreviations: CXCL9, C-X-C motif chemokine ligand 9; DSP, digital spatial profiling; FDR, false discovery rate; GSEI, gene set enrichment index, GZMK, granzyme K; IQR, interquartile range; VEGFR, VEGRF receptor.